Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

(2014) PA Kaufman et al.   CANCER RESEARCH

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells

(2014) Hao Deng et al.   PLoS One

Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells

(2012) Toshiro Shimo et al.   Breast Cancer

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

(2010) Junichi Kurebayashi et al.   BMC CANCER

Targeting Breast Cancer Stem Cells

(2010) Suling Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling

(2010) C. M. Fillmore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial)

(2009) Yasuo Ohashi et al.   BREAST CANCER RESEARCH AND TREATMENT

Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer

(2009) Junichi Kurebayashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature

(2009) Emmanuelle Charafe-Jauffret et al.   CANCER RESEARCH

Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

(2009) T. Tanei et al.   CLINICAL CANCER RESEARCH

Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On

(2009) Harikrishna Nakshatri et al.   Current Stem Cell Research & Therapy

Epithelial-Mesenchymal Transition and the Stem Cell Phenotype

(2008) Derek C. Radisky et al.   Cell Stem Cell

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

ALDH1 as a Functional Marker of Cancer Stem and Progenitor Cells

(2008) Julie Douville et al.   STEM CELLS AND DEVELOPMENT